BIORESTORAT.THERAP.DL-,01 Aktie

Starting August 7, BioRestorative Therapies has suspended all orders and shipments of its biocosmeceutical lines ExoCR and BioX until further notice while conducting an internal and regulatory review of documentation, sourcing, and regulatory status. A final decision on whether to discontinue or resume distribution has not been made. The company reports a market capitalization of $5.61 million and revenues of $360,000 in the last twelve months; the stock is down about 81% year to date. In addition, a $1 million revolving credit facility at 12% interest was arranged, and hedge fund Kaos Capital disclosed a 4.9% stake and is calling for a strategic review. » Plus sur de.investing.com

BioRestorative Therapies has entered a revolving credit agreement of up to $1 million with the Bowery Group; the loan carries interest of 12% p.a. (16% on default) and is due one year after closing. As part of the agreement three directors resigned and three Bowery‑nominated members — Mika Grasso, Katharyn Field and Jatinder Dhaliwal — were appointed to the board. The company has a market capitalization of $9.43 million, negative free cash flow of $11.9 million and a current ratio of 2.35; an activist (Kaos Capital) holds 4.9% and is pushing for strategic alternatives. » Plus sur de.investing.com

BioRestorative Therapies will present safety and blinded efficacy data from a fully enrolled phase‑2 study in chronic lumbar disc disease, as well as preclinical data on its exosome platform, at the ISCT annual meeting in Dublin on May 6. Lead candidate BRTX-100 is an autologous, cultured MSC product for the non‑surgical treatment of lumbosacral disc pain; the treatment is administered by injection into the damaged disc. The company manufactures in cGMP‑ and ISO‑7‑certified clean rooms and runs additional programs in obesity/metabolism as well as a BioCosmeceutical platform. » Plus sur de.investing.com